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Synthesis of Derivatives of 3-Aminoquinazolinone and  
2’-Deoxyguanosine as Potential Protein Tyrosine 
Kinase Inhibitors 
Kirk D. Wyatt, Laurie A. Witucki, Felix N. Ngassa 
Department of Chemistry, Grand Valley State University, Allendale, MI 49401 
ABSTRACT Protein kinases play an important role in post-translational cellular signaling by 
regulating cell growth, differentiation and apoptosis, among other cellular activities. Furthermore, protein 
kinase (PK) deregulation has been implicated in many diseases, including cancer. For this reason, there 
has been considerable interest in the development of PK inhibitors, which could lead to the discovery of 
new cancer-treating drugs. Derivatives of 3-aminoquinazolinone and 2’-deoxyguanosine were 
synthesized as potential ATP-competitive inhibitors of the Src and FAK protein tyrosine kinases, and the 
effectiveness of the synthesized derivatives as protein tyrosine kinase inhibitors was quantified using [γ-
32P]ATP radioisotope assays. The results of the assays indicated that none of the compounds synthesized 
were as effective as other previously discovered inhibitors. 
INTRODUCTION  
Protein kinases (PKs) play an important role in post-translational cellular signaling by regulating cell 
growth, differentiation and apoptosis; among other cellular activities. Protein tyrosine kinases (PTKs) are 
a class of protein kinases which catalyze the transfer of a phosphate group from ATP to a tyrosine 
residue. PK deregulation has been implicated in numerous diseases, with the most notable being cancer.1 
Given the association between PK deregulation and disease, it is no surprise that PKs have become some 
of the most extensively studied biological targets in drug discovery research, accounting for an estimated 
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20-30% of all drug discovery projects in the pharmaceutical industry. One major focus of these research 
efforts is the development of PK inhibitors which has received much attention after the FDA approval in 
2001 of the drug Gleevec—a PK inhibitor—for the treatment of certain forms of cancer. As a result of 
these efforts, numerous protein kinase inhibitors are currently in human clinical trials as cancer 
treatments.2 
Focal adhesion kinase (FAK) is a protein tyrosine kinase that was discovered less than twenty years 
ago, making its discovery relatively recent. Despite extensive efforts to characterize FAK and to 
understand its functions in cellular signaling, many questions regarding the precise role of FAK in the 
regulation of vital cellular functions remain unanswered. FAK is thought to play a role in the regulation 
of cellular activities such as cell growth, cell division, cell migration, and apoptosis.3 Further research has 
shown that human tumor cells displayed increased levels of FAK, as compared to those levels in non-
neoplastic cells from the same subject.4 Moreover, other studies have shown that FAK inhibition has led 
to apoptosis in human cancer cells, and that combining this inhibition with the inhibition of another PK 
such as EGFR or c-Src, has had the effect of further enhancing apoptosis.5,6 The Src family of PKs has 
also been shown to regulate a variety of cellular activities such as cell division, motility and apoptosis.7 
The activity of the Src family of kinases has been shown to be elevated in human breast and colon 
cancers, and their inhibition has been shown to cause mitotic arrest in human cancer cells.8 Given that Src 
and FAK have been shown to be deregulated in several types of human tumors, the development of 
selective inhibitors of these PKs has emerged to be a promising area of cancer research. 
Previous work in our laboratory resulted in the discovery of a 3-aminoquinazolinone derivative and a 
2’-deoxyadenosine derivative which were found to be effective inhibitors of the Src and FAK kinases.9 
Encouraged by these results, we decided to synthesize other derivatives of 3-aminoquinazolinone and 2’-
deoxyguanosine and test them as potential inhibitors of the FAK and Src PTKs. Herein, the results of the 
synthesis and inhibition studies involving various derivatives of 3-aminoquinazolinone and 2’-
deoxyguanosine are reported. 
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RESULTS AND DISCUSSION 
Imine and amide derivatives of 3-aminoquinazolinone are easy to prepare, and given the availability of 
a vast number of aldehydes and carboxylic acids (with which to react the parent compound) in our 
laboratory, we decided that preparing imine and amide derivatives would provide us with the greatest 
diversity of 3-aminoquinazolinone derivatives. Furthermore, as previous work in our laboratory resulted 
in the discovery of a 2’-deoxyadenosine derivative which was found to be an effective PTK inhibitor, we 
decided to pursue the synthesis of a broad array of 2’-deoxyguanosine (dG) derivatives given the 
structural similarity between 2’-deoxyadenosine and 2’-deoxyguanosine. 
Synthesis of 3-Aminoquinazolinone Derivatives  
3-Aminoquinazolinone was prepared according to a method reported in the literature, and subsequently 
reacted with either aldehydes to give imine derivatives or with acid chlorides to give amide derivatives 
(Scheme 1).10 Reacting 3-aminoquinazolinone (1) with the appropriate acid chloride in dry THF, in the 
presence of pyridine resulted in the formation of the amide derivatives 3a-c. Similarly, in a single step, the 
reaction of 3-aminoquinazolinone (1) with the appropriate aldehyde in the presence of a catalytic amount 
of acetic acid resulted in the formation of imine derivatives 2a-h. Examples of imine and amide 
derivatives synthesized are shown in Figure 1. 
Scheme 1. Preparation of imine and amide derivatives of 3-aminoquinazolinone 
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Figure 1. List of 3-aminoquinazolinone derivatives prepared 
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Synthesis of 2’-Deoxyguanosine Derivatives 
Derivatives of dG could not be synthesized directly from commercially-available dG. Instead, the sugar 
hydroxyl groups first had to be protected, and a sulfonate group introduced at O6 to facilitate SNAr 
displacement by alcohol and amine nucleophiles, as reported in the literature (Scheme 2).11 
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Scheme 2. Preparation of O6-alkyl–, O6-aryl– and N6-alkyl– derivatives of 2’-deoxyguanosine 
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Nucleophilic alcohols, amines and phenols promoted facile displacement of the sulfonate group resulting 
in moderate to good yields of the desired substituted products (Figure 2).   
Figure 2. List of 2’-deoxyguanosine derivatives prepared 
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 The activity of FAK and Src in the presence of 3-aminoquinazolinone derivatives and dG derivatives 
was quantified using a [γ-32P]ATP radioisotope labeling assay. As points of reference, the compounds 
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were tested alongside several commercially-available inhibitors (I-1, I-2, I-3, I-4, Figure 3) as well as the 
two lead compounds that generated this research project (RS-7A and DK-40 both refer to two different 
samples of the same 3-aminoquinazolinone lead compound; F-2 was the 2’-deoxyadenosine lead 
compound). In the graphs that follow, the activity of the kinase is shown in the presence of each 
compound. A low percent activity indicates that the compound is effective at inhibiting the kinase. 
Figure 3. Structures of known inhibitors 
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FAK Activity in the Presence of Inhibitors 
The activity of FAK in the presence of each of the inhibitors was quantified. A 10mM solution of each 
inhibitor (to give a concentration of 1mM when tested) was prepared for the assays; however, several of 
the inhibitors were not fully soluble in DMSO at 10mM, and therefore, the assays do not all reflect 
inhibition at a uniform concentration of the inhibitor. Nevertheless, these data were used to screen for 
any initial “hits” which could then be further investigated. Compound 8b was not tested here because the 
supply of kinase ran out during the assay. 
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Figure 4. Activity of FAK in the presence of inhibitors 
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Several activities were found to be in excess of 100%, and we suspect that this may be due to 
improperly calibrated pipettors. Not withstanding, the effectiveness of commercially-available inhibitors 
I-1 and I-4 is apparent. Lead compounds RS-7A and F-2 are also shown to exhibit some inhibition of the 
kinase, confirming previous results; however none of the novel inhibitors were shown to be more 
effective (within experimental error) than the lead compounds or the best commercially-available 
inhibitors. A second screening of compound 2c—the most promising of the inhibitors from the initial 
screening—alongside lead compound RS-7A showed that 2c displayed 74% activity, while the lead 
compound displayed 56% activity. Given these results, we concluded that none of the compounds 
prepared were effective inhibitors of FAK. 
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Src Activity in the Presence of Inhibitors 
Given the solubility issues, only those compounds that were soluble in DMSO at 10mM were tested in 
the initial screening with Src. 
Figure 5. Activity of Src in the presence of inhibitors 
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From this screening, the most promising of the novel inhibitors were 2e and 2h; however, neither was 
as effective as commercially-available inhibitors I-1, I-3, I-4 or lead compound DK-40. 
All of the novel inhibitors that were tested with Src in the next screening were tested at 0.167mM 
(except for 2h and 2e which were tested at 1mM). 
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Figure 6. Activity of Src in the presence of inhibitors 
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Compounds 2e and 2h were shown to effectively inhibit Src; however, these were tested at 1mM, and 
all other inhibitors had been tested at 0.167mM.  
Since all of the inhibitors have to be tested at a uniform concentration in order to compare them side-
by-side, another screen needed to be done to compare all of the inhibitors at the same concentration. 
Thus, in the next screen, 2e and 2h were tested alongside two other promising novel inhibitors of Src (7b 
and 7d), a commercially-available inhibitor and the two lead compounds at 0.1mM. 
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Figure 7. Activity of Src in the presence of inhibitors 
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These data indicate that the best of the novel Src inhibitors was 2h; however, it was tested as a crude 
product, and thus an assay with a pure product would be necessary to definitively identify the compound 
as an effective inhibitor. Compound 2e was found in other screens to be an effective inhibitor of Src; 
however, the results were not reproducible in this screen. Despite the fact that these inhibitors were 
somewhat effective, they were not as effective as commercially-available inhibitor I-3 or the two lead 
compounds RS-7A and F-2. 
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EXPERIMENTAL 
Synthesis of 3-Aminoquinazolinone Derivatives 
General Procedure for the Synthesis of Imine Derivatives of 3-Aminoquinazolinone (2a-h) 
Imine derivatives of 3-aminoquinazolinone were generally prepared by stirring the parent compound (1 
eq), the appropriate aldehyde (1 eq) and a few drops of AcOH in MeOH or EtOH at reflux for 24 hours 
under an inert nitrogen atmosphere. The reaction mixture was then slowly cooled to room temperature 
and chilled on ice to precipitate the product, which was isolated via vacuum filtration and rinsed with 
cold alcohol. 
General Procedure for the Synthesis of Amide Derivatives of 3-Aminoquinazolinone (3a-c) 
Amide derivatives of 3-aminoquinazolinone were generally prepared by stirring the parent compound 
(1 eq), the appropriate acid chloride (1.2 eq) and pyridine (1.5 eq) in dry THF at 0°C, then slowly 
bringing the reaction mixture to room temperature and stirring at room temperature for 24 hours under 
an inert nitrogen atmosphere. The reaction was quenched with saturated NaHCO3 and the reaction 
mixture was diluted with EtOAc, followed by sequential extractions with saturated NaHCO3 and 
saturated NaCl. The organic layer was dried over anhydrous Na2SO4. Evaporation of the organic 
solvents gave the crude product, which was recrystallized in methanol to give the final product. 
3-amino-4(3H)quinazolinone 1. The 3-aminoquinazolinone parent compound was prepared by 
stirring a mixture of 2-aminobenzhydrazide (1 eq) and triethyl orthoformate (1.08 eq) in ethanol (0.5 M) 
at reflux for 5.5 hours under an inert nitrogen atmosphere. More triethyl orthoformate (0.1 eq) was 
added to drive the reaction to completeness, and the reaction mixture was stirred o.n. at r.t. Reaction 
mixture was then stirred for 1 hour at reflux, then cooled to r.t. on benchtop and subsequently chilled on 
ice to precipitate all of the product, which was filtered under vacuum and rinsed with cold ethanol. 
Product was dried under vacuum. Second crop was obtained via filtration, and third crop via trituration 
to give 2.055g (60%) yield of a tan solid. M.P.(°C): 204-209, 1HNMR (400 MHz, DMSO-d6, δ): 8.33 (s, 
1H), 8.14 (d, 1H), 7.79 (t, 1H), 7.65 (d, 1H), 7.53 (t, 1H), 5.82 (s, 2H). 
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3-(4-Methylbenzylideneamino)quinazolin-4(3H)-one 2a. Methanol was used as the solvent, and the 
product (white solid) was oven-dried at 90-100°C for 1 hr to remove solvent impurities and give the final 
product with 55mg (35%) yield. M.P.(°C): 153-156, 1HNMR (300 MHz, DMSO-d6, δ): 9.2 (s, 1H), 8.6 
(s, 1H), 8.2 (d, 1H), 7.8 (overlapping, 3H), 7.7 (d, 1H), 7.6 (t, 1H), 7.3 (d, 2H), 2.4 (s, 3H) 
3-((E)-3-phenylallylidene)aminoquinazolin-4(3H)-one 2b. Methanol was used as the solvent and the 
product (white solid) was isolated with 132mg (77%) yield. M.P.(°C): 113-115, 1HNMR (400 MHz, 
DMSO-d6, δ): 9.0 (d, 1H), 8.4 (s, 1H), 8.2 (d, 1H), 7.8 (t, 1H), 7.7 (d overlapping 3H), 7.6 (t, 1H), 7.4 
(overlapping, 4H), 7.2 (dd, 1H). 
3-(4-Nitrobenzylideneamino)quinazolin-4(3H)-one 2c. Methanol was used as the solvent, and 3Å 
molecular sieves were added to the reaction mixture. TLC indicated no reaction progress after several 
hours, so more MeOH and one additional drop of AcOH was added, and the reaction was stirred at 
reflux overnight. TLC the next morning showed that the reaction was still incomplete. MeOH was 
evaporated on rotary evaporator, and the residual solid was dissolved in a minimal amount of hot DMF. 
The solution was cloudy-tan (presumably due to molecular sieves being ground up), so the solution was 
hot-filtered to give a clear/tan solution. DMF was then evaporated to give a solid, which was dissolved in 
hot EtOH, and two drops AcOH were added. The reaction mixture was stirred at reflux overnight, and 
the reaction mixture cooled to r.t. on benchtop, then chilled in an icebath. The precipitate (yellow solid) 
was isolated by vacuum filtration to give only 14mg (8%) yield. M.P.(°C): 231-237, 1HNMR (300 MHz, 
CDCl3, δ): 10.1 (s, 1H), 8.4 (s, 1H), 8.4 (overlapping, 3H), 8.0 (d, 2H), 7.8 (overlapping, 2H), 7.6 (t, 
1H). 
3-(3-Nitrobenzylideneamino)quinazolin-4(3H)-one 2d. Methanol was used as the solvent, and 3Å 
molecular sieves were added to the reaction mixture. TLC indicated no reaction progress after several 
hours, so more MeOH and one additional drop of AcOH was added, and the reaction was stirred at 
reflux overnight. TLC the next morning showed that the reaction was still incomplete. MeOH was 
evaporated on rotary evaporator, and the residual solid was dissolved in a minimal amount of hot DMF. 
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The solution was cloudy-tan (presumably due to molecular sieves being ground up), so the solution was 
hot-filtered to give a clear/tan solution. DMF was then evaporated to give a solid, which was dissolved in 
hot EtOH, and two drops AcOH were added. The reaction mixture was stirred at reflux overnight, and 
the reaction mixture cooled to r.t. on benchtop, then chilled in an icebath. The precipitate (yellow solid) 
was isolated by vacuum filtration to give only 32mg (18%) yield. M.P.(°C): 209-211, 1HNMR (300 
MHz, DMSO-d6, δ): 10.1 (s, 1H), 8.8 (s, 1H), 8.4 (s, 1H), 8.4 (d, 2H), 8.2 (d, 1H), 7.8 (overlapping, 
2H), 7.7 (t, 1H), 7.6 (t, 1H). 
3-(4-Hydroxybenzylideneamino)quinazolin-4(3H)-one 2e. Methanol was used as the solvent, and 
the product (brown/tan solid) was isolated with 47mg (29%) yield. M.P.(°C): 196-197, 1HNMR (400 
MHz, DMSO-d6, δ): 10.3 (br s, 1H), 9.0 (s, 1H), 8.5 (s, 1H), 8.2 (d, 1H), 7.8 (t, 1H), 7.7 (overlapping, 
3H), 7.5 (t, 1H), 6.9 (d, 2H). 
3-(Furan-2-ylmethyleneamino)quinazolin-4(3H)-one 2f. Methanol was used as the solvent, and the 
product (brown needles) was isolated with 32mg (22%) yield. M.P.(°C): 135-138, 1HNMR (400 MHz, 
CDCl3, δ): 9.6 (s, 1H), 8.4 (s,1H), 8.3 (d, 1H), 7.8 (m, 2H), 7.6 (s, 1H), 7.5 (t, 1H), 7.0 (d, 1H), 6.6 (q, 
1H). 
3-(Naphthalen-2-ylmethyleneamino)quinazolin-4(3H)-one 2g. Methanol was used as the solvent, 
and the product (white powder) was isolated with 82mg (45%) yield. M.P.(°C): 169-172, 1HNMR (400 
MHz, CDCl3, δ): 9.8 (s, 1H), 8.4 (s, 1H), 8.4 (d, 1H), 8.2 (s, 1H), 8.1 (d, 1H), 7.9 (d, 2H), 7.9 (d, 1H), 
7.8 (overlapping, 2H), 7.6 (overlapping, 3H). 
3-(Butylideneamino)quinazolin-4(3H)-one 2h. Butanal (1eq) was dissolved in toluene and five drops 
of AcOH were added. The mixture was stirred for five minutes, and then 3-aminoquinazolinone (1 eq) 
was added. The flask was connected to a Dean-Stark apparatus filled with toluene and stirred at reflux 
overnight. The reaction mixture was cooled to r.t. on benchtop, then chilled on ice. No solid precipitated. 
Toluene was evaporated, and the residual oil was dissolved in hot EtOH, cooled to r.t., and chilled on 
ice. No solid precipitated. Upon addition of water, a milky-white emulsion formed. Water and ethanol 
 14 
were evaporated in vacuo to give a tan/light brown solid. Trituration in DCM was attempted to purify 
the solid; however, TLC and 1HNMR indicated that impurities were still present in the white solid that 
was obtained. 66mg (50%) of the crude product was obtained, and the crude product was used for the 
assay. M.P.(°C): 133-137, 165-185, 1HNMR (300 MHz, CDCl3, δ): 8.4 (t, 1H), 8.3 (d, 1H) 8.1 (app. t, 
1H), 7.8 (q, 1H), 7.6 (t, 1H), 7.4 (q, 1H),  2.5 (q, 2H), 1.7 (m, 2H), 1.0 (t, 3H). 
4-Methoxy-N-(4-oxoquinazolin-3(4H)-yl)benzamide 3a. Due to a mishap, toluene was added to the 
reaction mixture after 24 hours of mixing, but before the work-up was conducted. The crude product 
(light tan solid) was recrystallized in methanol, and the resulting solid was oven-dried at 90°C-100°C for 
1 hr to remove solvent impurities apparent in 1HNMR. The dried solid was then triturated in 75:25 
EtOAc:Hexanes to give the final product (white solid) with 22mg (12%) yield. M.P.(°C): 168-169, 
1HNMR (400 MHz, DMSO-d6, δ): 11.7 (s, 1H), 8.4 (s, 1H), 8.2 (dd, 1H), 8.0 (overlapping, 2H), 7.9 (d, 
1H), 7.8 (d, 1H), 7.6 (t, 1H), 7.1 (d, 2H), 3.9 (s, 3H). 
N-(4-Oxoquinazolin-3(4H)-yl)benzamide 3b. The crude product was oven-dried at 90°C-100°C for 
1 hr to remove solvent impurities and give the final product (tan solid) with 88mg (54%) yield. M.P.(°C): 
186-188, 1HNMR (300 MHz, DMSO-d6, δ): 11.9 (s, 1H), 8.5 (s, 1H), 8.2 (d, 1H), 8.0 (overlapping, 
3H), 7.9 (t, 1H), 7.8 (d, 1H) 7.6 (broad overlapping, 3H). 
4-Methyl-N-(4-oxoquinazolin-3(4H)-yl)benzamide 3c. The same procedure was followed as in the 
other amide syntheses, except that the acid chloride was formed in situ by stirring p-toluic acid (1.2 eq) 
and oxalyl chloride (1.4 eq) in THF (5 mL) and DMF (two drops) for one hour. The reaction was 
quenched by the addition of pyridine (1 eq). After the reaction, the crude product was recrystallized in 
MeOH to give the final product (tan solid) with 44mg (25%) yield. M.P.(°C): 202, 1HNMR (300 MHz, 
DMSO-d6, δ): 11.8 (s, 1H), 8.4 (s, 1H), 8.2 (d, 1H), 7.9 (overlapping, 3H), 7.8 (d, 1H), 7.6 (t, 1H), 7.4 
(d, 2H), 2.4 (s, 3H). 
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Synthesis of 2’-Deoxyguanosine Derivatives 
General Materials and Methods 
NMR spectra of 7a-3 and 8a-b were recorded at 300 MHz in deacidified CDCl3. Deacidification was 
performed by percolating the solvent through solid NaHCO3 and basic alumina. Syntheses of 7a-3 and 
8a-b were performed in oven-dried screw-capped vials equipped with oven-dried stirbars and purged 
with nitrogen. 
General Procedure for the Preparation of N6-alkyl– Derivatives of dG 
N6-alkyl– derivatives of dG were prepared by stirring a mixture of sulfonated TBDMS-dG (1 eq), Et3N 
(5 eq) and the appropriate amine (5 eq) in 1,2-DME with 4Å molecular sieves at 50°C for 23 hours 
under an inert atmosphere. The reaction mixture was then decanted into a separatory funnel and diluted 
with EtOAc. The organic layer was extracted with 10% (w/v) citric acid and saturated NaHCO3. The 
organic layer was then dried over anhydrous Na2SO4. Evaporation of organic solvents gave the crude 
product, which was purified by column chromatography generally using DCM to load the compound and 
2% MeOH in DCM to elute the product. Alike fractions were collected and the organic solvents were 
evaporated to leave behind the product, which was dried overnight under vacuum. 
General Procedure for the Preparation of O6-alkyl–, and O6-aryl– Derivatives of dG 
O6-alkyl–, and O6-aryl– derivatives of dG were prepared by stirring a mixture of sulfonated TBDMS-
dG (1 eq), DABCO (2 eq) and the appropriate alcohol (5 eq) in 1,2-DME with 4Å molecular sieves at 
room temperature under an inert atmosphere. After 30 minutes of stirring, DBU was added and the 
reaction mixture was stirred at room temperature for 24 hours under an inert atmosphere. The reaction 
mixture was then decanted into a separatory funnel and diluted with EtOAc, followed by sequential 
extractions with 1N NaOH and H2O. The organic layer was dried over anhydrous Na2SO4, and the 
solvents were evaporated to give the crude product, which was purified via column chromatography 
using either a combination of DCM to load the compound and 2% MeOH in DCM to elute the product 
or a 4% MeOH in DCM to load the compound and elute the product, depending on the polarity of the 
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product. Alike fractions were collected and the organic solvents were evaporated to leave behind the 
product, which was dried overnight under vacuum. 
2-Amino-6-(benzylamino)-9-[2-deoxy-3,5-bis-O-(tert-butyldimethylsilyl)-β-D-erythro-pento-
furanosyl]purine 7a. Due to a mishap, the vial was not purged with nitrogen until fifteen minutes after 
reaction start. This did not appear to have any adverse effect on the outcome of the experiment. The 
reaction mixture was stirred for 24 hours and the product (tan/white solid) was obtained with 66.4mg 
(77%) yield. Rf(silica/2% MeOH in DCM) = 0.41, 1HNMR (300 MHz, deacidified CDCl3, δ): 7.74 (s, 
1H8), 7.3 (m, 5H, ArH), 6.32 (app. t, 1H1), 5.88 (s, 1H, NH), 4.78 (s, 2H, NH2), 4.72 (s, 2H, NCH2), 
4.54 (app. m, 1H3), 4.00 (app. q, 1H4), 3.78 (app. dd, 2H5), 2.58 (app. m, 1H2), 2.32 (app. ddd, 1H2), 
1.73, 1.26, 0.89 (s, 18H, t-butyl), 0.08 (s, 12H, SiCH3). 
2-Amino-6-(allylamino)-9-[2-deoxy-3,5-bis-O-(tert-butyldimethylsilyl)-β-D-erythro-pento-
furanosyl]purine 7b. The reaction mixture was stirred for 23 hours, and after the first chromatographic 
separation using DCM to load the compound and 2% MeOH in DCM to elute the product, the product 
was not clean as judged by 1HNMR and TLC. The crude product was rechromatographed using the same 
solvent system, but this second separation was not successful either. Trituration in cold hexane was 
attempted; however, it did not result in any further purification. Finally, the crude product was 
rechromatographed using 1:1 hexane:ethyl acetate to load the compound and elute the product. Alike 
fractions were collected and the organic solvents were evaporated to leave behind the clean product, 
which was dried overnight under vacuum. The product (white solid) was obtained with 38.1mg (48%) 
yield. Rf(silica/2% MeOH in DCM) = 0.36, 1HNMR (300 MHz, deacidified CDCl3, δ): 7.74 (s, 1H8), 
6.27 (t, 1H1), 5.94 (m, 1H, =CH), 5.58 (br s, 1H, NH), 5.27 (dd, 1H, =CHtrans), 5.13 (dd, 1H, =CHcis), 
4.72 (br s, 2H, NCH2), 4.56 (m, 1H3), 4.20 (br s, 2H, NH2) 3.94 (m, 1H4), 3.76 (m, 2H5), 2.56 (quint, 
1H2), 2.31 (m, 1H2), 2.13 (br s, residual H2O), 0.89 (s, 18H, t-butyl), 0.09 (s, 12H, SiCH3). 
2-Amino-6-(4-methylpiperazino)-9-[2-deoxy-3,5-bis-O-(tert-butyldimethylsilyl)-β-D-erythro-
pento-furanosyl]purine 7c. The reaction mixture was stirred for 25 hours, and the solvents used for the 
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purification were DCM to load the compound and 10% MeOH in DCM to elute the product, which was 
isolated as a yellow oil in 62.2mg (73%) yield. Rf(silica/2% MeOH in DCM) = 0.02, 1HNMR (300 MHz, 
deacidified CDCl3, δ): 7.68 (s, 1H8), 6.29 (t, 1H1), 4.64 (br s, 2H, NH2), 4.53 (m, 1H3), 4.21 (br s, 4H, 
N-C-N-CH2), 3.94 (q, 1H4), 3.73 (m 2H5), 2.48 (t, m overlapping, 5H, 4CH3-N-CH2, 1H2), 2.31 (s, m 
overlapping, 4H, 3N-CH3, 1H2), 0.88 (s, 18H, t-butyl), 0.04 (s, 12H, SiCH3). 
2-Amino-6-morpholino-9-[2-deoxy-3,5-bis-O-(tert-butyldimethylsilyl)-β-D-erythro-pento-
furanosyl]purine 7d. The reaction mixture was stirred for 25 hours, and the solvents for the purification 
were DCM to load the compound and 5% MeOH in DCM to elute the product, which was isolated as a 
yellow oil with 64.8mg (82%) yield. Rf(silica/2% MeOH in DCM) = 0.32, 1HNMR (300 MHz, 
deacidified CDCl3, δ): 7.70 (s, 1H8), 6.30 (t, 1H1), 4.65 (br s, 2H, NH2), 4.55 (m, 1H3), 4.20 (app. t, 4H, 
CH2-N-CH2), 3.94 (m, 1H4), 3.75 (overlapping m, 6H, 4CH2-O-CH2, 2H5), 2.52 (app. quint, 1H2), 2.31 
(m, 1H2), 0.89 (s, 18H, t-butyl), 0.08 (s, 12H, SiCH3). 
O6-Benzyl-3’-5’-bis-O-tert-butyldimethylsilyl-2’-deoxyguanosine 8a. The reaction mixture was 
stirred for 24 hours. The solvent system for the purification was DCM to load the compound and 2% 
MeOH in DCM to elute the product (yellow oil with crystal formation evident) with 51.7mg (60%) 
yield.. Rf(silica/2% MeOH in DCM) = 0.66, 1HNMR (300 MHz, deacidified CDCl3, δ)1: 7.89 (s, 1H8), 
7.48 (d, 2H, ArH), 7.36 (overlapping, 2H, ArH), 7.31 (overlapping, 1H, ArH), 6.31 (t, 1H1), 5.5 (s, 2H, 
OCH2), 4.84 (br s, 2H, NH2), 4.56 (m, 1H3), 3.98 (m, 1H4), 3.77 (overlapping dd, 2H5), 2.53 (quint, 
1H2), 2.35 (quint, 1H2), 0.90 (s, 18H, t-butyl), 0.08 (s, 12H, SiCH3). 
O6-Phenyl-3’-5’-bis-O-tert-butyldimethylsilyl-2’-deoxyguanosine 8b. The reaction mixture was 
stirred for 24 hours. The solvent system for the purification was 4% MeOH in DCM to load the column 
and elute the product (slightly oily yellow/white solid) with 64.8mg (77%) yield. Rf(silica/2% MeOH in 
DCM) = 0.63, 1HNMR (300 MHz, deacidified CDCl3, δ): 7.99 (s, 1H), 7.38 (m, 2H, ArH), 7.20 
                                               
1
 
1HNMR showed minor uncharacterized impurities 
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(overlap, 3H, ArH), 6.33 (t, 1H1), 4.80 (br s, 2H, NH2), 4.58 (m, 1H3), 3.98 (m, 1H4), 3.79 (qd, 2H5), 
2.57 (app quint, 1H2), 2.37 (m, 1H2), 0.91 (s, 18H, t-butyl), 0.08 (s, 12H, SiCH3). 
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